Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 9 August 2017

Biocartis Group NV: Invitation to the extraordinary shareholders' meeting

Biocartis Group NV    

Published: 07:00 CEST 09-08-2017 /GlobeNewswire /Source: Biocartis Group NV / : BCART /ISIN: BE0974281132

Biocartis Group NV: Invitation to the extraordinary shareholders' meeting


Wednesday, 9 August 2017, 07:00 CEST

Invitation to the
extraordinary shareholders' meeting

Mechelen, Belgium, 9 August 2017
- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant holders, directors and statutory auditor to the extraordinary shareholders' meeting that will be held on Monday 11 September 2017 at 10:00 a.m. CEST at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium.


The agenda of the extraordinary shareholders' meeting includes the proposed appointment of Herman Verrelst as director of the Company and approval of a new warrant plan for Herman Verrelst as the Chief Executive Officer of the Company. He will be taking up the role of Chief Executive Officer as from 1 September 2017.


In order to be admitted to the extraordinary shareholders' meeting, the holders of securities issued by the Company must comply with Article 536 of the Belgian Companies Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the extraordinary shareholders' meeting can be consulted on the website of the Company.


--- END ---

More information:

Renate Degrave

Manager Corporate Communications & Investor Relations Biocartis

email rdegrave@biocartis.com

tel +32 15 631 729 | mobile +32 471 53 60 64


About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.



The Biocartis trademark and logo are trademarks of Biocartis and are used and registered in Europe. Idylla(TM) is a registered trademark in the United States and other countries. The Idylla(TM) trademark and logo are trademarks of and used by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be prohibited by applicable law. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.


Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to update or revise any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Biocartis Group NV, Generaal De Wittelaan 11 b3, Mechelen 2800, Belgium
If you would like to unsubscribe and stop receiving these e-mails click here.